ALX Oncology Holdings Inc.
ALXOALX Oncology is a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapies that target the CD47 checkpoint pathway.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
Profile
ALX Oncology is a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapies that target the CD47 checkpoint pathway. The company leverages its proprietary protein engineering platform to create therapies, such as its lead candidate evorpacept, designed to block the "don't eat me" signal used by cancer cells while minimizing the hematologic toxicities common in first-generation CD47 inhibitors. Its strategy centers on combining these innate immune system activators with existing anti-cancer antibodies and treatments to improve outcomes in both solid tumors and hematologic malignancies.
A clinical-stage innovator developing a differentiated CD47 blocker with an inactive Fc domain designed to provide a superior safety profile and broader therapeutic window than competitors.
Questions, answered.
- What is ALX Oncology Holdings Inc.'s market cap?
- ALX Oncology Holdings Inc. (ALXO) has a market capitalization of $271.8M and trades on NASDAQ.
- Who are ALX Oncology Holdings Inc.'s competitors?
- ALX Oncology Holdings Inc.'s key competitors include Exelixis, Gilead Sciences, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does ALX Oncology Holdings Inc. partner with?
- ALX Oncology Holdings Inc.'s notable partners include Jazz Pharmaceuticals plc, Sanofi, Zymeworks Inc., and others.
- What subsidiaries does ALX Oncology Holdings Inc. have?
- ALX Oncology Holdings Inc.'s subsidiaries include ALX Oncology Limited.
- Where is ALX Oncology Holdings Inc. headquartered?
- ALX Oncology Holdings Inc. is headquartered in United States of America and employs approximately 74 people. It has been publicly traded since 2020.